Gossamer Bio Q1 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 42 minutes ago
0mins
Should l Buy GOSS?
Source: seekingalpha
- Earnings Performance: Gossamer Bio reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $16.96M, a 71.3% year-over-year increase, surpassing market expectations by $13.14M, suggesting a significant rise in product acceptance and demand that could lay the groundwork for future growth.
- Cash Reserves: As of March 31, Gossamer had $99 million in cash, cash equivalents, and marketable securities, providing ample liquidity to support ongoing R&D and market expansion, thereby enhancing financial stability.
- Regulatory Uncertainty: Cantor downgraded Gossamer Bio due to unclear regulatory pathways for seralutinib, which may raise investor concerns about the company's future direction and impact stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.330
Low
10.00
Averages
12.33
High
15.00
Current: 0.330
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Launches Exchange Offer for Convertible Notes
- Exchange Offer Initiated: Gossamer Bio has launched an exchange offer for its existing 5.00% Convertible Senior Notes, proposing to exchange them for up to $72 million in new 7.50% Convertible Senior Secured Notes, which is expected to improve the company's capital structure and reduce financial costs.
- High Support from Noteholders: Approximately 75.2% of existing noteholders have signed a transaction support agreement to back the exchange offer, reflecting market confidence in the company's restructuring plan and enhancing the liquidity of the bonds.
- Advantages of New Bond Terms: The new bonds will mature in 2030 with an interest rate of 7.50% and conversion rights, which are expected to attract more investors and enhance the company's financing capabilities and market competitiveness.
- Key Timeline: The exchange offer will expire on June 16, 2026, with an early tender deadline of June 1, 2026, ensuring timely participation will enable the company to successfully complete its debt restructuring and optimize its capital structure.
See More
Gossamer Bio Q1 Earnings Report Analysis
- Earnings Performance: Gossamer Bio reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $16.96M, a 71.3% year-over-year increase, surpassing market expectations by $13.14M, suggesting a significant rise in product acceptance and demand that could lay the groundwork for future growth.
- Cash Reserves: As of March 31, Gossamer had $99 million in cash, cash equivalents, and marketable securities, providing ample liquidity to support ongoing R&D and market expansion, thereby enhancing financial stability.
- Regulatory Uncertainty: Cantor downgraded Gossamer Bio due to unclear regulatory pathways for seralutinib, which may raise investor concerns about the company's future direction and impact stock performance.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting extreme market pessimism regarding its future prospects and severely undermining investor confidence in the company's management.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which may have led to significant investor losses, highlighting the potential reputational risks for the company.
- Listing Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks and further exacerbate investor concerns.
See More
Gossamer Bio to Report Q1 2026 Financial Results
- Earnings Release Announcement: Gossamer Bio has announced that it will report its Q1 2026 financial results on May 18, 2026, indicating ongoing progress in the treatment of pulmonary arterial hypertension, which is expected to provide investors with critical financial data and business updates.
- Management Conference Call: Following the earnings release, the management team will host a conference call and webcast at 8:00 a.m. ET on May 18, 2026, aimed at discussing the financial results in detail and providing the latest corporate updates to enhance investor confidence.
- Dial-in Information: The domestic dial-in number is 1-800-715-9871, while the international dial-in number is 1-646-307-1963, with Conference ID 3974570, ensuring investors can easily participate in the discussion and improve transparency.
- Webcast Replay Availability: An audio replay of the conference will be available for 30 days on the company's investor section of the website, further enhancing information accessibility and helping investors stay informed about the company's developments.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, could result in broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, highlighting the company's lack of transparency in disclosures, which could impact its future fundraising capabilities and market reputation.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Gossamer Bio and certain executives, alleging violations of federal securities laws on behalf of investors who purchased shares between June 16, 2025, and February 20, 2026, seeking to recover damages.
- Allegations of Misrepresentation: The complaint claims that the defendants misled investors by promoting positive results from the Phase 3 PROSERA study while concealing significant adverse facts regarding the study's design, particularly the failure to adequately control for placebo responses at Latin American sites, which inflated the stock prices.
- Investor Participation Opportunity: Affected investors have until June 1, 2026, to request to be appointed as lead plaintiff in the case, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- No-Cost Representation: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds for investors, minimizing financial risk for those involved in the lawsuit.
See More
Gossamer Bio Launches Exchange Offer for Convertible Notes
- Exchange Offer Initiated: Gossamer Bio has launched an exchange offer for its existing 5.00% Convertible Senior Notes, proposing to exchange them for up to $72 million in new 7.50% Convertible Senior Secured Notes, which is expected to improve the company's capital structure and reduce financial costs.
- High Support from Noteholders: Approximately 75.2% of existing noteholders have signed a transaction support agreement to back the exchange offer, reflecting market confidence in the company's restructuring plan and enhancing the liquidity of the bonds.
- Advantages of New Bond Terms: The new bonds will mature in 2030 with an interest rate of 7.50% and conversion rights, which are expected to attract more investors and enhance the company's financing capabilities and market competitiveness.
- Key Timeline: The exchange offer will expire on June 16, 2026, with an early tender deadline of June 1, 2026, ensuring timely participation will enable the company to successfully complete its debt restructuring and optimize its capital structure.
See More
Gossamer Bio Q1 Earnings Report Analysis
- Earnings Performance: Gossamer Bio reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $16.96M, a 71.3% year-over-year increase, surpassing market expectations by $13.14M, suggesting a significant rise in product acceptance and demand that could lay the groundwork for future growth.
- Cash Reserves: As of March 31, Gossamer had $99 million in cash, cash equivalents, and marketable securities, providing ample liquidity to support ongoing R&D and market expansion, thereby enhancing financial stability.
- Regulatory Uncertainty: Cantor downgraded Gossamer Bio due to unclear regulatory pathways for seralutinib, which may raise investor concerns about the company's future direction and impact stock performance.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting extreme market pessimism regarding its future prospects and severely undermining investor confidence in the company's management.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which may have led to significant investor losses, highlighting the potential reputational risks for the company.
- Listing Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks and further exacerbate investor concerns.
See More
Gossamer Bio to Report Q1 2026 Financial Results
- Earnings Release Announcement: Gossamer Bio has announced that it will report its Q1 2026 financial results on May 18, 2026, indicating ongoing progress in the treatment of pulmonary arterial hypertension, which is expected to provide investors with critical financial data and business updates.
- Management Conference Call: Following the earnings release, the management team will host a conference call and webcast at 8:00 a.m. ET on May 18, 2026, aimed at discussing the financial results in detail and providing the latest corporate updates to enhance investor confidence.
- Dial-in Information: The domestic dial-in number is 1-800-715-9871, while the international dial-in number is 1-646-307-1963, with Conference ID 3974570, ensuring investors can easily participate in the discussion and improve transparency.
- Webcast Replay Availability: An audio replay of the conference will be available for 30 days on the company's investor section of the website, further enhancing information accessibility and helping investors stay informed about the company's developments.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence, which may lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, could result in broader legal liabilities for the company.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, highlighting the company's lack of transparency in disclosures, which could impact its future fundraising capabilities and market reputation.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Gossamer Bio and certain executives, alleging violations of federal securities laws on behalf of investors who purchased shares between June 16, 2025, and February 20, 2026, seeking to recover damages.
- Allegations of Misrepresentation: The complaint claims that the defendants misled investors by promoting positive results from the Phase 3 PROSERA study while concealing significant adverse facts regarding the study's design, particularly the failure to adequately control for placebo responses at Latin American sites, which inflated the stock prices.
- Investor Participation Opportunity: Affected investors have until June 1, 2026, to request to be appointed as lead plaintiff in the case, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- No-Cost Representation: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds for investors, minimizing financial risk for those involved in the lawsuit.
See More
